SCHEMBL4885782

SCHEMBL4885782

CCCC(O)OC(=O)c1cc(C(=O)O)ccc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 1/20 0.43
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.41
PTPN11 Q06124 2/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
ACE2 Q9BYF1 2/20 0.38
PLA2G4B P0C869 2/20 0.37
CDC25A P30304 1/20 0.37
CDC25B P30305 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TP53 P04637 1/20 0.37
MYC P01106 1/20 0.37
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11699744 0.87 KDM4E (0.44) ALDH1A1KDM4ETSHRMAPK1PTPN11
SCHEMBL4885779 0.87 ALDH1A1 (0.50) ALDH1A1KDM4ETSHRMAPK1LMNA
SCHEMBL1308816 0.82 ALDH1A1 (0.61) ALDH1A1KDM4ETSHRMAPK1LMNA
Terephthalic Acid SCHEMBL8439001 0.82 MAPT (0.49) ALDH1A1TSHRMAPK1PLA2G4BTP53
SCHEMBL2061233 0.82 MAPT (0.49) ALDH1A1TSHRMAPK1PLA2G4BTP53
SCHEMBL1960510 0.80 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1PTPN11PLA2G4B
SCHEMBL18096524 0.80 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1PTPN11PLA2G4B
SCHEMBL2284064 0.80 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1PTPN11PLA2G4B
SCHEMBL2185343 0.79 KMT2A (0.48) ALDH1A1LMNARAB9APLA2G4BTP53
SCHEMBL2920879 0.79 KDM4E (0.45) ALDH1A1KDM4ETSHRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax ALEMBIC PHARMACEUTICALS LIMITED (IN) 2022-07-07 US claimed
WO-2020225738-A1 PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX ALEMBIC PHARMACEUTICALS LIMITED (IN) 2020-11-12 WO claimed
EP-1847257-B1 Solid preparation comprising enteric solid dispersion SHINETSU CHEMICAL CO (JP) 2017-11-22 EP claimed
US-20140370091-A1 Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-18 US claimed
EP-2813218-A1 Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same Shin-Etsu Chemical Co., Ltd. (JP) 2014-12-17 EP claimed
US-20080038340-A1 Solid dosage form of enteric solid dispersion and method for producing the same SHIN-ETSU CHEMICAL CO., LTD. 2008-02-14 US claimed
EP-1886673-A2 Solid dosage form of enteric solid dispersion and method for producing the same Shin-Etsu Chemical Co., Ltd. (JP) 2008-02-13 EP claimed
US-20070248682-A1 SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-10-25 US claimed
EP-1847257-A2 Solid preparation comprising enteric solid dispersion Shin-Etsu Chemical Co., Ltd. (JP) 2007-10-24 EP claimed
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION 2025-07-31 US disclosed
EP-4479092-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS Purdue Research Foundation (US) 2024-12-25 EP disclosed
WO-2023154171-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS PURDUE RESEARCH FOUNDATION (US) 2023-08-17 WO disclosed
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax ALEMBIC PHARMACEUTICALS LIMITED (IN) 2022-07-07 US disclosed
US-11292793-B2 Solid dispersions of amorphous Lumateperone p-Tosylate DR. REDDY'S LABORATORIES LIMITED (IN) 2022-04-05 US disclosed
US-20080038340-A1 Solid dosage form of enteric solid dispersion and method for producing the same SHIN-ETSU CHEMICAL CO., LTD. 2008-02-14 US disclosed
EP-1886673-A2 Solid dosage form of enteric solid dispersion and method for producing the same Shin-Etsu Chemical Co., Ltd. (JP) 2008-02-13 EP disclosed
US-20070248682-A1 SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1847257-A2 Solid preparation comprising enteric solid dispersion Shin-Etsu Chemical Co., Ltd. (JP) 2007-10-24 EP disclosed
US-20070196399-A1 ENTERIC-COATED PREPARATION COVERED WITH ENTERIC COATING MATERIAL FOR SITE-SPECIFIC DELIVERY OF DRUG TO SITE WITHIN THE SMALL INTESTINE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2007-08-23 US disclosed
EP-1820498-A2 Enteric-coated preparation for site-specific delivery of drug to site within the small intestine Shin-Etsu Chemical Co., Ltd. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292793-B2 Solid dispersions of amorphous Lumateperone p-Tosylate HTR2A, HTR2C, HTR1A ALDH1A1 2652/4885KDM4E 3180/4885TSHR 100/4885
US-20250242031-A1 POLYMER SALTS FOR IMPROVED DRUG DELIVERY FROM AMORPHOUS SOLID DISPERSIONS SRI, SYNGR2, PSD ALDH1A1 3898/4885KDM4E 835/4885TSHR 4586/4885
US-20220211725-A1 Pharmaceutical Composition Comprising Venetoclax U2AF1, SF3B1, SF3B3 ALDH1A1 3436/4885KDM4E 1233/4885TSHR 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.